Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-055752
Filing Date
2025-04-18
Accepted
2025-04-18 08:00:19
Documents
18
Period of Report
2025-05-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A clsd-20250417.htm   iXBRL DEF 14A 1395391
2 GRAPHIC img143323038_0.jpg GRAPHIC 38406
3 GRAPHIC img143323038_1.jpg GRAPHIC 260315
4 GRAPHIC img143323038_2.jpg GRAPHIC 4001717
5 GRAPHIC img143323038_3.jpg GRAPHIC 793092
  Complete submission text file 0000950170-25-055752.txt   15403304

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20250417.xsd EX-101.SCH 7930
21 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20250417_htm.xml XML 704790
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37783 | Film No.: 25849241
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)